Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations

AAPS Journal

Volumn 5, Issue 2, 2003, Pages

  Andya, James D ^a   Hsu, Chung C ^a   Shire, Steven J ^a  

^a GENENTECH INC   (United States)

Author keywords

Aggregation; FT IR spectrometry; Protein formulation; Protein stability; Recombinant humanized monoclonal antibody

Indexed keywords

EID: 55449104956     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps050210     Document Type: Article

References (31)

1. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903-917.
2. Shire SJ. Challenges and issues in the development of formulations of protein pharmaceuticals. In: Wu-Pong S, Rojanasakul Y, eds. Biopharmaceutical Drug Design and Development. Totowa, NJ: Humana Press Inc., 1999:205-238.
3. Hsu CC, Ward CA, Pearlman R, Nguyen HM, Yeung DA, Curley JG. Determining the optimum residual moisture in lyophilized protein pharmaceuticals. Drug Dev Biol Stand. 1991;74:235-271.
4. Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res. 1994;11:12-20.
5. Dill KA. Dominant forces in protein folding. Biochemistry. 1990;29:7133-7155.
6. Schulz GE, Schirmer RH. In: Cantor CR, ed. Principles of Protein Structure. New York, NY: Springer-Verlag Inc., 1979;27-45.
7. Dong A, Prestrelski SJ, Allison SD, Carpenter JF. Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J Pharm Sei. 1995;84:415-424.
8. Costantino HR, Langer R, Klibanov AM. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sei. 1994;83:1662-1669.
9. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14:969-975.
10. Pikal MJ. Freeze-drying of proteins: process, formulation, and stability. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. Washington, DC: American Chemical Society; 1994;120-133.
11. Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry. 1989;28:3916-3922.
12. Prestrelski SJ, Tedeschi N, Arakawa T, Carpenter JF. Dehydration-induced conformation transitions in proteins and their inhibition by stabilizers. Biophys J. 1993;65:661-671.
13. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sei U S A. 1992;89:4285-4289.
14. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623-2632.
15. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
16. Andya JD, Wu S, Hsu CC, Shire SJ. The effect of sugars and buffer excipients on the stabilization of a lyophilized formulation for an anti-IgE humanized monoclonal antibody. Pharm Res. 1996;13:S78.
17. Andya JD, Maa Y-F, Costantino HR, et al. The effect of formulation excipients on protein stability and aerosol performance of spraydried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res. 1999;16:350-358.
18. Cleland J, Lam X, Kendrick B, et al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sei. 2001;90:310-321.
19. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effects of moisture on the stability of a lyophilized humanized monoclonal antibody. Pharm Res. 2001;18:1345-1353.
20. Connors KA. The Karl Fisher titration of water. Drug Dev Ind Pharm. 1988;14:1891-1903.
21. Dong A, Huang P, Caughey WS. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry. 1990;29:3303-3308.
22. Riddles PW, Blakeley RLB, Zerner B. Ellman's reagent: 5,5′-dithiobis(2-nitrobenzoic acid): a reexamination. Anal Biochem. 1979;94:75-81.
23. Fu F-N, DeOliverira DB, Trumble WR, Sakar HK, Singh BR. Secondary structure estimation of proteins using the amide III region of Fourier transform infrared spectroscopy: applications to analyze calcium-binding-induced structural changes in calsequestrin. Appl Spectrosc. 1994;48:1432-1441.
24. Costantino HR, Andya JD, Shire SJ, Hsu CC. Fourier-transform infrared spectroscopic analysis of the secondary structure of recombinant humanized immunoglobulin G. Pharm Sei. 1997;3:121-128.
25. Surewicz WK, Manisch HH. New insight into protein secondary structure from resolution-enhanced infrared spectra. Biochim Biophys Acta. 1988;952:115-130.
26. Sarver RW, Drueger WC. An infrared and circular dichroism combined approach to the analysis of protein secondary structure. Anal Biochem. 1991;199:61-67.
27. Hageman MJ. The role of moisture in protein stability. Drug Dev Ind Pharm. 1988;14:2047-2070.
28. Hsu CC, Ward CA, Pearlman R, Nguyen HM, Yeung DA, Curley JG. Determining the optimum residual moisture in lyophilized protein pharmaceuticals. Drug Dev Biol Standard. 1991;74:235-271.
29. Padlan EA. On the nature of antibody combining sites: unusual structural features that may confer on these sites an enhanced capacity of binding ligands. Proteins: Struct Func Genet. 1990;7:112-124.
30. Costantino HR, Curley JG, Hsu CC. Determining the water sorption monolayer of lyophilized pharmaceutical proteins. J Pharm Sei. 1997;86:1390-1393.
31. Chen T. Formulation concern of protein drugs. Drug Dev Ind Pharm. 1992;18:1311-1354.